The answer is clear. Cancer treatments have very d

Quote:

---

The answer is clear. Cancer treatments have very different price tags than HIV treatments. The difference between being able to charge $ 120.000 or $ 30.000. While it might be technically possible to package/ label/name the same Leronlimab differently for different purposes I do not feel having different price tags would be accepted by insurers/the public/government.
Thus I think there can only be one price tag.

---

I agree there needs to be one price tag. But the negatives of a high price tag far outway the positives.

A $60,000 price tag in combo would relegate leronlimab to an almost exclusively MDR3+ patient population and lose us the much greater MDR2 population.

In cancer we would corner the market for those already progressed to metastasis, but lose out on our use as a prophylactic in cancers that are prone to metastasis.

In NASH our patient population would predominate in late stage NASH but we lose out on the majority that are in early and mid-stage.

The higher the price the more likely insurance companies and HHS will to turn down it's use except in the more serious cases.

One other thing to consider is that in the near future drug sales from other countries to the U.S. may be allowed. A lower price will mean a lower differential between the two and less likely to be bought elsewhere. With sales being booked overseas we would only get the much lower royalty rates.